Genmab A/S (GMAB)
38.48
+3.73
(+10.73%)
USD |
NASDAQ |
Oct 05, 16:00
38.65
+0.17
(+0.44%)
After-Hours: 05:46
Genmab Enterprise Value : 26.74B for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 26.74B |
| October 02, 2026 | 24.52B |
| October 01, 2026 | 24.40B |
| September 30, 2026 | 25.07B |
| September 29, 2026 | 25.01B |
| September 28, 2026 | 24.88B |
| September 25, 2026 | 24.86B |
| September 24, 2026 | 24.56B |
| September 23, 2026 | 24.52B |
| September 22, 2026 | 24.80B |
| September 21, 2026 | 24.48B |
| September 18, 2026 | 24.51B |
| September 17, 2026 | 24.39B |
| September 16, 2026 | 24.31B |
| September 15, 2026 | 24.16B |
| September 14, 2026 | 23.26B |
| September 11, 2026 | 23.16B |
| September 10, 2026 | 23.01B |
| September 09, 2026 | 23.50B |
| September 08, 2026 | 23.79B |
| September 04, 2026 | 23.83B |
| September 03, 2026 | 24.31B |
| September 02, 2026 | 24.20B |
| September 01, 2026 | 23.64B |
| August 31, 2026 | 23.57B |
| Date | Value |
|---|---|
| August 28, 2026 | 23.61B |
| August 27, 2026 | 24.13B |
| August 26, 2026 | 23.92B |
| August 25, 2026 | 24.28B |
| August 24, 2026 | 23.48B |
| August 21, 2026 | 23.74B |
| August 20, 2026 | 23.72B |
| August 19, 2026 | 24.13B |
| August 18, 2026 | 23.45B |
| August 17, 2026 | 23.38B |
| August 14, 2026 | 22.84B |
| August 13, 2026 | 22.48B |
| August 12, 2026 | 22.53B |
| August 11, 2026 | 22.19B |
| August 10, 2026 | 22.20B |
| August 07, 2026 | 22.43B |
| August 06, 2026 | 21.58B |
| August 05, 2026 | 21.24B |
| August 04, 2026 | 21.10B |
| August 03, 2026 | 20.89B |
| July 31, 2026 | 21.01B |
| July 30, 2026 | 20.87B |
| July 29, 2026 | 20.80B |
| July 28, 2026 | 21.08B |
| July 27, 2026 | 20.96B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma A/S | 14.56B |
| Zealand Pharma A/S | 644.22M |
| AbbVie, Inc. | 533.92B |
| Bavarian Nordic A/S | 2.184B |
| Evaxion AS | 19.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 302.57M |
| Revenue (Quarterly) | 1.153B |
| Total Expenses (Quarterly) | 850.79M |
| EPS Diluted (Quarterly) | 0.4903 |
| Gross Profit Margin (Quarterly) | 92.73% |
| Profit Margin (Quarterly) | 26.23% |
| Earnings Yield | 3.28% |
| Operating Earnings Yield | 5.43% |
| Normalized Earnings Yield | 4.004 |